https://pharminent.com/pro-hub-locked/ 2026-09-06T02:10:32Z Pharminent en Pro Hub — Members Only 2026-09-06T02:10:29Z Blog https://pharminent.com/pro-hub/ 2026-09-06T01:36:30Z Pharminent en Pro Hub 2026-09-05T22:26:10Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-september-4-2026/ 2026-09-05T21:19:27Z Pharminent en Oncology Intelligence Digest • September 4, 2026 2026-09-05T21:19:24Z Blog https://pharminent.com/glp-1-competitive-market/glp-1-competitive-market-digest-weekly-september-4-2026/ 2026-09-05T21:08:49Z Pharminent en GLP-1 Competitive Market Digest • Weekly • September 4, 2026 2026-09-05T21:08:47Z Blog https://pharminent.com/market-access/market-access-intelligence-weekly-digest-september-4-2026/ 2026-09-05T20:56:00Z Pharminent en MARKET ACCESS INTELLIGENCE • Weekly Digest • September 4, 2026 2026-09-05T20:55:58Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-september-3-2026/ 2026-09-04T22:02:35Z Pharminent en Rare Disease & Gene Therapy Digest • September 3, 2026 2026-09-04T22:02:32Z Blog https://pharminent.com/ionis-wins-first-ever-fda-approval-for-alexander-disease-with-zanvastro/ 2026-09-04T20:32:20Z Pharminent en Ionis Wins First-Ever FDA Approval for Alexander Disease with Zanvastro 2026-09-04T20:32:16Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-september-4-2026/ 2026-09-04T18:19:34Z Pharminent en Strategic News Watch • September 4, 2026 2026-09-04T18:07:39Z Blog